Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Gross Margin for 5 consecutive years, with 91.61% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 67.0% to 91.61% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 89.73% through Dec 2025, changed 0.0% year-over-year, with the annual reading at 89.73% for FY2025, 0.0% changed from the prior year.
  • Gross Margin for Q4 2025 was 91.61% at Rhythm Pharmaceuticals, up from 89.28% in the prior quarter.
  • The five-year high for Gross Margin was 112.77% in Q4 2022, with the low at 50.0% in Q2 2021.
  • Average Gross Margin over 5 years is 87.72%, with a median of 88.57% recorded in 2021.
  • The sharpest move saw Gross Margin soared 4583bps in 2022, then plummeted -2611bps in 2023.
  • Over 5 years, Gross Margin stood at 87.01% in 2021, then rose by 30bps to 112.77% in 2022, then fell by -23bps to 86.66% in 2023, then rose by 5bps to 90.95% in 2024, then grew by 1bps to 91.61% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 91.61%, 89.28%, and 88.57% for Q4 2025, Q3 2025, and Q2 2025 respectively.